Literature DB >> 8547120

A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages.

K Tohyama1, Y Tohyama, T Nakayama, T Ueda, T Nakamura, Y Yoshida.   

Abstract

A novel long-term cultured interleukin (IL)-3-dependent human myelodysplastic cell line, MDS92, was shown to contain several myeloid-lineage cells such as neutrophils, macrophages, eosinophils, and a small number of megakaryocyte-lineage cells. Therefore this cell line possesses at least bipotential characteristics of myeloid- and megakaryocyte-lineages. Granulocyte colony-stimulating factor clearly promoted the neutrophil alkaline phosphatase activity of MDS92 cells. To the contrary, the incidence and growth of CD41-positive cells were hardly affected by the addition of IL-6, IL-11, c-mpl ligand (thrombopoietin, TPO) or erythropoietin. TPO slightly supported the growth of CD34-positive cell fraction, but not CD41-positive cell fraction of MDS92 cells in combination with IL-3 or Steel factor. This cell line will be a useful tool for the study of MDS stem cells, but the mechanism of commitment of differentiation in MDS stem cells remains unknown.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547120     DOI: 10.1111/j.1365-2141.1995.tb05391.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.

Authors:  N Sugino; M Kawahara; G Tatsumi; A Kanai; H Matsui; R Yamamoto; Y Nagai; S Fujii; Y Shimazu; M Hishizawa; T Inaba; A Andoh; T Suzuki; A Takaori-Kondo
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

2.  Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.

Authors:  Zheng Zhang; Qi He; Ying Tao; Juan Guo; Feng Xu; Ling-Yun Wu; You-Shan Zhao; Dong Wu; Li-Yu Zhou; Ji-Ying Su; Lu-Xi Song; Chao Xiao; Xiao Li; Chun-Kang Chang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

3.  An MDS xenograft model utilizing a patient-derived cell line.

Authors:  G W Rhyasen; M Wunderlich; K Tohyama; G Garcia-Manero; J C Mulloy; D T Starczynowski
Journal:  Leukemia       Date:  2013-12-11       Impact factor: 11.528

4.  Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes.

Authors:  Xiang Li; Feng Xu; ChunKang Chang; John Byon; Thalia Papayannopoulou; H Joachim Deeg; A Mario Marcondes
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

5.  A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.

Authors:  Jing Fang; Xiaona Liu; Lyndsey Bolanos; Brenden Barker; Carmela Rigolino; Agostino Cortelezzi; Esther N Oliva; Maria Cuzzola; H Leighton Grimes; Celia Fontanillo; Kakajan Komurov; Kyle MacBeth; Daniel T Starczynowski
Journal:  Nat Med       Date:  2016-06-13       Impact factor: 53.440

6.  Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

Authors:  Garrett W Rhyasen; Lyndsey Bolanos; Jing Fang; Andres Jerez; Mark Wunderlich; Carmela Rigolino; Lesley Mathews; Marc Ferrer; Noel Southall; Rajarshi Guha; Jonathan Keller; Craig Thomas; Levi J Beverly; Agostino Cortelezzi; Esther N Oliva; Maria Cuzzola; Jaroslaw P Maciejewski; James C Mulloy; Daniel T Starczynowski
Journal:  Cancer Cell       Date:  2013-07-08       Impact factor: 31.743

7.  Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.

Authors:  Feng Xu; Qi He; Xiao Li; Chun-Kang Chang; Ling-Yun Wu; Zheng Zhang; Li Liu; Wen-Hui Shi; Yang Zhu; You-Shan Zhao; Shu-Cheng Gu; Cheng-Ming Fei; Juan Guo; Dong Wu; Liyu Zhou
Journal:  Sci Rep       Date:  2014-12-04       Impact factor: 4.379

8.  LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia.

Authors:  Goichi Tatsumi; Masahiro Kawahara; Ryusuke Yamamoto; Masakatsu Hishizawa; Katsuyuki Kito; Takayoshi Suzuki; Akifumi Takaori-Kondo; Akira Andoh
Journal:  Leukemia       Date:  2019-11-01       Impact factor: 11.528

9.  Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.

Authors:  Takayuki Tsujioka; Akira Yokoi; Yoshitaro Itano; Kentaro Takahashi; Mamoru Ouchida; Shuichiro Okamoto; Toshinori Kondo; Shin-ichiro Suemori; Yumi Tohyama; Kaoru Tohyama
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

10.  Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.

Authors:  Antònia Banús-Mulet; Amaia Etxabe; Josep Maria Cornet-Masana; Miguel Ángel Torrente; María Carmen Lara-Castillo; Laura Palomo; Meritxell Nomdedeu; Marina Díaz-Beyá; Francesc Solé; Benet Nomdedeu; Jordi Esteve; Ruth M Risueño
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.